Therefore, in this study, we aim to identify predictive markers that influence efficacy and attempt to create a novel nomogram predicting the prognosis of advanced NSCLC patients who were treated with anti-PD-1 plus chemotherapy with or without antiangiogenic therapy, which is beneficial for guiding clinical treatment decisions. Here, PDCD1 is linked to non-small cell lung carcinoma.